ACS Medicinal Chemistry Letters
November 10, 2025
Anna C. Renner, Robert B. Kargbo
High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that...
Journal of Psychoactive Drugs
November 10, 2025
Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes et al.
1 citation
Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experiences of participants in remission...
European Neuropsychopharmacology
November 7, 2025
Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al.
12 citations
Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...
OPAL (Open@LaTrobe) (La Trobe University)
November 5, 2025
Alberto Liardi (22305679), Fernando E. Rosas (9595503), Robin L. Carhart-Harris (5923571) et al.
From left to right, results refer to LSD, ketamine, and psilocybin drugs. Panel rows represent (a) the raw values of PID atoms, (b) the NMI-normalised PID atoms, and (c) the NuMIT-normalised PID atoms. The dashed black lines are drawn at zero. (P-values calculated with a one-sample t-test against the zero-mean null hypothesis. *: ppp<0.001).
Zenodo (CERN European Organization for Nuclear Research)
November 4, 2025
Uri Bertocchi, Amit Schwartz, Gali Umschweif et al.
preprint
Background: Psilocybin, a serotonergic psychedelic compound, has demonstrated long-term antidepressant effects, yet its underlying mechanisms remain unclear. Emerging evidence suggests that epigenetic modifications, particularly 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), may play a role in its therapeutic action. Unlike passive demethylation, which requires cell division and...
PsyArXiv
November 2, 2025
Sebastian Ehmann, Nathan M. Hager, Paul S. Regier et al.
preprint
Background and AimsThe ongoing opioid epidemic remains a major public health crisis in the United States, with over 100,000 opioid-related deaths annually. Mental health disorders are strongly associated with opioid use disorder (OUD), compounding risks of misuse and overdose. Emerging evidence indicates that psychedelics may be associated with reduced risk of OUD. This study aimed to estimate...
Polo del Conocimiento
November 1, 2025
Jhon Bryan Paca Aucancela
El Trastorno de Estrés Postraumático (TEPT) constituye un desafío clínico significativo debido a las altas tasas de resistencia a la farmacoterapia convencional y el abandono de las terapias tradicionales. Ante este escenario, el actual "renacimiento psicodélico" propone el uso controlado de sustancias psicoactivas como herramientas para potenciar el procesamiento del trauma. El objetivo de...
Global Journal of Research in Biology and Pharmacy
October 31, 2025
Ifeyinwa Adar Opoku
Psychedelics, including psilocybin, lysergic acid diethylamide, and dimethyltryptamine, and entactogens such as 3,4-methylenedioxymethamphetamine are being investigated for treatment-resistant depression, post-traumatic stress disorder, anxiety, and substance use disorders. These compounds act primarily through serotonin 5-HT2A receptor agonism (psychedelics) or monoamine release (MDMA),...
Translational Psychiatry
October 31, 2025
Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al.
3 citations
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
DELOS Desarrollo Local Sostenible
October 29, 2025
Sandele Amorim Dos Santos, Gabriela Rocha Dos Santos
Os transtornos de ansiedade e a compulsão alimentar representam desafios significativos para a saúde pública global, frequentemente associados a altos índices de resistência aos tratamentos convencionais. Diante desse cenário, este estudo tem como objetivo revisar as evidências científicas sobre o uso terapêutico de plantas psicodélicas — ayahuasca, psilocibina e jurema preta — no manejo da...